Outcome of the Board Meeting held today, i.e., January 23, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.6 pts less than Nifty Microcap 250 and 3.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Zenotech Laboratories approved unaudited standalone financial results for Q3 FY26 and nine months ended December 31, 2025. Revenue from operations grew to Rs 1,182.60 lakhs in Q3 (up ~15.7% YoY from Rs 1,022.16 lakhs) and to Rs 3,069.70 lakhs for 9M FY26 (up ~10.2% YoY from Rs 2,786.25 lakhs). However, profit after tax for 9M fell sharply to Rs 207.87 lakhs from Rs 432.99 lakhs a year earlier, weighed down by a one-time Rs 190.49 lakhs tax adjustment linked to the Section 115BAA opt-in and a Rs 29.89 lakhs exceptional charge for new Labour Codes. Employee expenses rose ~24% YoY in 9M, pressuring operating profitability with EBITDA proxy margin compressing from ~45.7% to ~34.1%. The Board also appointed Mr. Nikkhil Venilal Kothhari as Independent Director for 5 years, noted the end of Mr. Chintan Jitendra Shah's tenure, and reconstituted the Audit, NRC, and Stakeholders Relationship Committees effective January 27, 2026.
Despite healthy top-line growth, shareholders should watch the sharp 9M PAT decline and meaningful margin compression caused by higher staff costs and one-time tax/exceptional items. The auditor issued a clean limited review report, and the new independent director adds governance depth ahead of the committee changes.